Compare AbbVie Inc (ABBV) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI Indonesia ETF — how do they compare? AbbVie Inc trades at $250.5 (market cap $438.19B), while iShares MSCI Indonesia ETF trades at $12.48. The key difference: AbbVie Inc pays a 2.79% dividend while iShares MSCI Indonesia ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | EIDO | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | — |
52-Week High | $263.58 | $19.22 |
52-Week Low | $197.38 | $10.80 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.19, up 1.28% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust immunology drug performance from Skyrizi and Rinvoq are offsetting Humira patent losses, driving revenue growth to $61.16B in 2025. The stock is near its pivot point of $247, with support at $245 and resistance at $249.
The outlook remains positive with a consensus price target of $281.33, though high P/E of 70.05 and looming patent cliffs in the 2030s present risks. Dividend growth and institutional accumulation support the buy case, but margin compression and debt levels warrant monitoring.
EIDO, the iShares MSCI Indonesia ETF, trades at $12.91, up 2.38% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows support and resistance clustered around $13. Recent news highlights Indonesia's economic initiatives, including AI integration in government programs and reforestation plans, while facing challenges from foreign capital outflows and central bank rate hikes to support the rupiah.
The outlook for EIDO is mixed, with low valuation offering potential upside, but weak price action and high financial sector exposure limit gains. Risks include geopolitical volatility and dependence on commodity markets, though government reforms could boost long-term growth. Investors should weigh bargain valuations against macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
